Abstract
The mdr1-type P-glycoproteins (P-gps) confer multidrug resistance to cancer cells by active extrusion of a wide range of drugs from the cell. To study their physiological roles, we have generated mice genetically deficient in themdr1bgene [mdr1b(−/−) mice] and in both themdr1aandmdr1bgenes [mdr1a/1b(−/−) mice]. In spite of the host of functions speculatively attributed to the mdr1-type P-gps, we found no physiological abnormalities in either strain. Viability, fertility, and a range of histological, hematological, serum–chemical, and immunological parameters were not abnormal inmdr1a/1b(−/−) mice. The high level of mdr1b P-gp normally present in the pregnant uterus did not protect fetuses from a drug (digoxin) in the bloodstream of the mother, although the protein did reduce drug accumulation in the adrenal gland and ovaries. Pharmacologically,mdr1a/1b(−/−) mice behaved similarly to the previously analyzedmdr1a(−/−) mice, displaying, for instance, increased brain penetration and reduced elimination of digoxin. However, both mdr1a and mdr1b P-gps contributed to the extrusion of rhodamine from hematopoietic progenitor cells, suggesting a potential role for the endogenous mdr1-type P-gps in protection of bone marrow against cytotoxic anticancer drugs. This, and the normal viability ofmdr1a/1b(−/−) mice, has implications for the use of P-gp-blocking agents in cancer and other chemotherapy.mdr1a/1b(−/−) mice should provide a useful model system to further test the pharmacological roles of the drug-transporting P-gps and to analyze the specificity and effectivity of P-gp-blocking drugs.
Bibliography
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M. J. M., Fibbe, W. E., & Borst, P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting)âP-glycoproteins. Proceedings of the National Academy of Sciences, 94(8), 4028â4033.
Authors
13
- Alfred H. Schinkel (first)
- Ulrich Mayer (additional)
- Els Wagenaar (additional)
- Carla A. A. M. Mol (additional)
- Liesbeth van Deemter (additional)
- Jaap J. M. Smit (additional)
- Martin A. van der Valk (additional)
- Arie C. Voordouw (additional)
- Hergen Spits (additional)
- Olaf van Tellingen (additional)
- J. Mark J. M. Zijlmans (additional)
- Willem E. Fibbe (additional)
- Piet Borst (additional)
References
41
Referenced
742
10.1146/annurev.bi.58.070189.001033
10.1016/0006-2952(92)90666-7
10.1016/0165-6147(94)90322-0
10.1146/annurev.ge.29.120195.003135
- T Tsuruo, H Iida, S Tsukagoshi, Y Sakurai Cancer Res 41, 1967–1972 (1981). / Cancer Res by Tsuruo T (1981)
10.1200/JCO.1989.7.4.415
- J M Ford, W N Hait Pharmacol Rev 42, 155–199 (1990). / Pharmacol Rev by Ford J M (1990)
10.1200/JCO.1993.11.9.1629
10.1016/0092-8674(86)90595-7
10.1016/0092-8674(86)90594-5
10.1016/S0021-9258(18)80173-9
10.1128/mcb.10.4.1652-1663.1990
- J M Croop, M Raymond, D Haber, R J Arceci, P Gros, D E Housman Mol Cell Biol 9, 1346–1350 (1989). / Mol Cell Biol by Croop J M (1989)
10.1016/0092-8674(94)90212-7
10.1073/pnas.84.21.7735
10.1073/pnas.86.2.695
10.1172/JCI118214
10.1172/JCI118699
10.1111/j.1476-5381.1996.tb15775.x
10.1073/pnas.94.5.2031
10.1016/0959-8049(96)00063-9
10.1016/S0021-9258(18)35757-0
10.1016/0092-8674(93)90380-9
- S Childs, R Lin Yeh, E Georges, V Ling Cancer Res 55, 2029–2034 (1995). / Cancer Res by Childs S (1995)
10.1084/jem.157.3.1070
-
H Spits, H IJssel, C Terhorst, J E de Vries J Immunol 128, 95–99 (1982).
(
10.4049/jimmunol.128.1.95
) / J Immunol by Spits H (1982) - A Sparreboom, O van Tellingen, W J Nooijen, J H Beijnen Cancer Res 56, 2112–2115 (1996). / Cancer Res by Sparreboom A (1996)
10.1073/pnas.92.19.8901
10.1073/pnas.85.12.4350
- M M Gottesman Cancer Res 53, 747–754 (1993). / Cancer Res by Gottesman M M (1993)
10.1128/mcb.10.4.1642-1651.1990
10.1182/blood.V80.11.2729.2729
10.1182/blood.V83.9.2451.2451
10.1007/BF01754414
-
J M Witkowski, S P Li, G Gorgas, R A Miller J Immunol 153, 658–665 (1994).
(
10.4049/jimmunol.153.2.658
) / J Immunol by Witkowski J M (1994) 10.1002/eji.1830241208
- S Gupta, S Aggarwal Immunologist 4, 86–90 (1996). / Immunologist by Gupta S (1996)
10.1038/372549a0
10.1016/0092-8674(91)90141-K
10.1084/jem.175.6.1443
10.1084/jem.183.4.1797
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 10:43 a.m.) |
Deposited | 2 years, 4 months ago (April 22, 2023, 8:31 a.m.) |
Indexed | 2 days, 14 hours ago (Aug. 23, 2025, 9:14 p.m.) |
Issued | 28 years, 4 months ago (April 15, 1997) |
Published | 28 years, 4 months ago (April 15, 1997) |
Published Online | 28 years, 4 months ago (April 15, 1997) |
Published Print | 28 years, 4 months ago (April 15, 1997) |
@article{Schinkel_1997, title={Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins}, volume={94}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.94.8.4028}, DOI={10.1073/pnas.94.8.4028}, number={8}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Schinkel, Alfred H. and Mayer, Ulrich and Wagenaar, Els and Mol, Carla A. A. M. and van Deemter, Liesbeth and Smit, Jaap J. M. and van der Valk, Martin A. and Voordouw, Arie C. and Spits, Hergen and van Tellingen, Olaf and Zijlmans, J. Mark J. M. and Fibbe, Willem E. and Borst, Piet}, year={1997}, month=apr, pages={4028–4033} }